Navigation Links
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell

ung's team set out to address two obstacles to gene therapy for pancreatic cancer: lack of a targeted gene expression system that hits the cancer hard but spares normal tissue, and the need for an animal model that allows monitoring of tumor growth and metastasis without having to kill and dissect the animal.

They solved the monitoring problem by modifying two lines of pancreatic cancer to stably express firefly luciferace enzyme - the bioluminescent agent that lights up fireflies. This allowed live imaging of the mice to monitor cancer progression.

The researchers already had developed several components of the gene expression system. Led by first author Xiaoming Xie, Ph.D., a postdoctoral fellow and now instructor in Hung's department, the team used those components and pieces developed elsewhere to painstakingly build what became C-VISA-BikDD.

They used a gene-based targeting promoter called CCKAR known to be active in pancreatic cancer but not in healthy pancreatic tissue. The problem with pancreatic-cancer-specific gene promoters such as CCKAR, Hung says, is that they select narrowly for cancer cells but are not highly active once they get there. The success of gene therapy depends on efficient gene expression after delivery.

A system using a viral promoter such as CMV has the opposite problem: strong activity but indiscriminate delivery of the therapeutic gene to healthy tissue, which increases toxicity. The team's goal was to retain CCKAR's selectivity while boosting its activity to levels seen in CMV promoter-driven therapy.

To strengthen activity, the team added two key components: a regulatory gene sequence known as WPRE and the two-step transcriptional amplification system (TSTA) known to amplify activity of the prostate-specific antigen (PSA) promoter.

This enhanced C-VISA package increased gene activity levels by 67.6 percent to 287 percent over the CMV-driven therapy in three lines of pancreatic cancer. Lab exp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
5. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:9/30/2014)... Summary This report presents the ... regarding their Information & Communications Technology (ICT) investment ... allocate their ICT budgets across the core areas ... communications, and consulting. Key Findings ... that X% of respondents anticipate an increase in ...
(Date:9/30/2014)... Investor-Edge has initiated coverage on ... ), Aeterna Zentaris Inc. (NASDAQ: AEZS ), ... Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation ... be accessed at: http://investor-edge.com/register . On ... 4,505.85, down 0.14%, the Dow Jones Industrial Average finished ...
(Date:9/30/2014)... , Sept. 30, 2014  Come fall, many children, ... or "what" they want to be for Halloween. And, ... look with decorative contact lenses bought without a prescription. ... year that people purchase and wear contact lenses without ... American Eye-Q ® consumer survey, 17 percent of ...
Breaking Medicine Technology:ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 2ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3
(Date:9/30/2014)... OH (PRWEB) September 30, 2014 ... blades sporting the iconic pink ribbon in support of ... a popular month for businesses and non-profits to “go ... worthwhile cause. , AutoTex PINK is a woman-owned company ... wipers. They are committed to partnering with their ...
(Date:9/30/2014)... 30, 2014 Teeth replacement and restoration ... Institute in Oxnard and Thousand Oaks, Calif., is in ... to provide training on full mouth rehabilitation. , “Full ... implants, providing cosmetic dentistry, correcting bite issues, and resolving ... Dr. Jivraj, who has traveled to India to speak ...
(Date:9/30/2014)... 30, 2014 Loffler Companies, an ... technology and services was recognized by BEI as ... (FCE) in 2013. This prestigious rating means that ... time and for an extended period following, optimizing ... 20 years BEI Services has been the trusted ...
(Date:9/30/2014)... In honor of National Breast Cancer Awareness Month ... battles, Incredible Veins, Body & Skin is offering survivors ... , “For cancer patients who receive radiation treatment, ... their skin to accurately aim the radiation on the ... they decide to have their tattoo removed as the ...
(Date:9/30/2014)... 2014 Julie Kuriakose, MD; ... , will discuss how restaurants can become more allergy-friendly ... dietary restrictions at the 2014 Allergy Eats Food ... October 21 in New York City. , “I’m extremely ... to such an engaged industry audience. As food allergies ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... This strategy beat out either therapy alone, researchers found ... combination of cognitive behavior therapy plus antidepressant drugs is ... thoughts and behavior in depressed teens, new research shows. ... October issue of the journal Archives of General ...
... Health Inc. (Amex: OPK ),has announced the appointment ... Dr. Goldschmidt is the Senior Vice President for Medical,Affairs ... Miller School of,Medicine. Dr. Goldschmidt formerly served as Chairman ... "We are delighted to welcome an exceptional healthcare ...
... Cottage Hospital,which has served thousands of patients from ... 85 years, has rejoined the Henry Ford,Health System. ... Health,System. In 1998, Cottage became part of the Bon ... part of the joint venture,Henry Ford Health System owned ...
... Summit speakers Kenneth,Thorpe, Ph.D. of Partnership to Fight ... on Health, WASHINGTON, Oct. 1 Overhauling ... candidates, but one top,expert believes any serious proposal ... PhD., helped launch the Partnership to,Fight Chronic Disease ...
... 1 Crdentia Corp. (OTC Bulletin,Board: CRDT), a ... posted an exclusive interview on their website with,Michael ... In the interview, Mr. Yao describes how Crdentia,s ... facility contracts and 1,000 travel nurse,needs nationwide. He ...
... that typically fight bacteria, study finds , MONDAY, Oct. ... urban air pollution, shuts down early immune responses in ... vulnerable to bacteria and other foreign invaders, research shows. ... with increased cardiovascular and pulmonary hospitalizations and deaths, but ...
Cached Medicine News:Health News:Drug Plus Psychotherapy Best Treatment for Depressed Teens 2Health News:OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors 2Health News:OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors 3Health News:Grosse Pointe's Cottage Hospital Joins Henry Ford Health System 2Health News:Grosse Pointe's Cottage Hospital Joins Henry Ford Health System 3Health News:URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum 2Health News:URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum 3Health News:Crdentia's National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentia's Travel Nurse Division 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: